AURA vs REPL

Analysts rate Aura Biosciences, Inc.

(AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aura Biosciences, Inc.

(AURA) delivered a total return of -56. 7%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: REPL returned -41. 4% versus AURA's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Replimune Group, Inc.

(REPL) is the lower-risk stock at 0. 84β versus Aura Biosciences, Inc. 's 1. 68β — meaning AURA is approximately 100% more volatile than REPL relative to the S&P 500. On balance sheet safety, Aura Biosciences, Inc. (AURA) carries a lower debt/equity ratio of 13% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Replimune Group, Inc.

grew EPS 5. 2% year-over-year, compared to -0. 6% for Aura Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aura Biosciences, Inc.

(AURA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AURA leads at 0. 0% versus 0. 0% for REPL. At the gross margin level — before operating expenses — AURA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Replimune Group, Inc.

(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Aura Biosciences, Inc. (AURA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REPL: -41. 4%, AURA: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.